Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
viernes, 21 de junio de 2024
FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy?utm_medium=email&utm_source=govdelivery
LEVIDYS is an adeno-associated virus vector-based gene therapy indicated in individuals at least 4 years of age:
For the treatment of Duchenne muscular dystrophy (DMD) in patients who are ambulatory and have a confirmed mutation in the DMD gene.
For the treatment of DMD in patients who are non-ambulatory and have a confirmed mutation in the DMD gene (1, 12.2) The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin (noted hereafter as “micro-dystrophin”). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/elevidys?utm_medium=email&utm_source=govdelivery
No hay comentarios:
Publicar un comentario